The goal of this forum is to describe the value criteria currently employed to assess medication adherence enhancing interventions (MAEIs), to provide an overview of reimbursed MAEIs currently available in European countries and to discuss with forum participants on how to overcome the challenges related to the implementation of MAEIs.

On average, medication adherence to long-term pharmacotherapies is only 50% which has been shown to cause major clinical and economic burden. In the past decade, several MAEIs have been developed which have demonstrated proven benefits in improving patient outcomes. Little is known about the implementation of MAEIs in routine clinical practice. To our knowledge, there is a gap in the scientific literature with regards to the health technology assessment (HTA) and reimbursement of MAEIs.

This forum will present MAEI evaluation criteria identified by the ISPOR Medication Adherence and Persistence Special Interest Group (MAP SIG) through the systematic literature review of 308 studies published between 2018 and 2020 and a comprehensive overview of reimbursed MAEIs available in 39 countries based on a recent survey performed by the European Network to Advance Best practices & technoLogy on medication adherencE (ENABLE). The forum leaders will discuss outcome measures considered for the assessment of MAEIs in clinical trials, and HTA and reimbursement challenges of adherence technologies and programs. Discussion will be followed by an audience participation, which will include polling questions on value criteria, HTA and reimbursement aspects of MAEIs. Participants will be encouraged to share their experiences and recommendations for paving the way for MAEIs to be implemented in the future. The concluding period will allow for wrap up and opportunities for questions and answers.